Brauner S, Eriksson-Dufva A, Hietala MA et al (2020) Comparison between Rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol 77(8):974–981

Article  PubMed  Google Scholar 

Chen X, Zhao Q, Hou Y et al (2016) Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis. Br J Clin Pharmacol 82(1):41–52

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen R, Fu R, Lin Z, Huang C, Huang W (2023) The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus 32(1):94–100

Article  PubMed  CAS  Google Scholar 

Cutter G, Xin H, Aban I, Burns TM, Allman PH, Farzaneh-Far R, Duda PW, Kaminski HJ (2019) Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment. Muscle Nerve 60(6):707–715

Article  PubMed  PubMed Central  Google Scholar 

Dhillon S (2018) Eculizumab: a review in generalized myasthenia gravis. Drugs 78(3):367–376

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dhillon S (2021) Telitacicept: first approval. Drugs 81(14):1671–1675

Article  PubMed  CAS  Google Scholar 

Fichtner ML, Jiang R, Bourke A et al (2020) Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol 11:776

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gerischer L, Doksani P, Hoffmann S, Meisel A (2025) New and emerging biological therapies for myasthenia gravis: a focussed review for clinical decision-making. BioDrugs 39(2):185–213

Article  PubMed  PubMed Central  CAS  Google Scholar 

Germinal centers are associated with postthymectomy myasthenia gravis in patients with thymoma; Ectopic germinal centers in the thymus accurately predict prognosis of myasthenia gravis after thymectomy, Mod. Pathol.: an Official Journal of the United States and Canadian Academy of Pathology, Inc (2022).

Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023–1036

Article  PubMed  CAS  Google Scholar 

Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37(2):141–149

Article  PubMed  Google Scholar 

Howard JF Jr, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976–986

Article  PubMed  CAS  Google Scholar 

Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R, ADAPT Investigator Study Group (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526–536

Article  PubMed  CAS  Google Scholar 

Kim H, Lim Y-M, Lee E-J et al (2018) Factors predicting remission in thymectomized patients with acetylcholine receptor antibody positive myasthenia gravis. Muscle Nerve 58:796–800

Article  PubMed  CAS  Google Scholar 

Koneczny I (2020) Update on IgG4-mediated autoimmune diseases: new insights and new family members. Autoimmun Rev 19(10):102646

Article  PubMed  CAS  Google Scholar 

Lee I, Leach JM, Aban I, McPherson T, Duda PW, Cutter G (2022) One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: from the MG patient registry. Muscle Nerve 66(4):411–420

Article  PubMed  PubMed Central  Google Scholar 

Lin J, Li Y, Gui M, Bu B, Li Z (2024) Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study. Ther Adv Neurol Disord 14(17):17562864241251476

Article  Google Scholar 

Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H (2016) Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German Neurological Society. J Neurol 263(8):1473–1494

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nowak RJ, Dicapua DB, Zebardast N et al (2011) Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 4:259–266

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nowak RJ, Coffey CS, Goldstein JM et al (2021) Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: The BeatMG Study. Neurology 98(4):e376–e389

Google Scholar 

Palace J, Newsom-Davis J, Lecky B, Myasthenia Gravis Study Group (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50(6):1778–1783. https://doi.org/10.1212/WNL.50.6.1778

Article  PubMed  CAS  Google Scholar 

Petersson M, Feresiadou A, Jons D, Ilinca A, Lundin F, Johansson R, Budzianowska A, Roos AK, Kågström V, Gunnarsson M, Sundström P, Piehl F, Brauner S (2021) Patient-reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG Study. Neurology 97(14):e1382–e1391

Article  PubMed  PubMed Central  CAS  Google Scholar 

Piehl F, Eriksson-Dufva A, Budzianowska A et al (2022) Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: The RINOMAX randomized clinical trial. JAMA Neurol 79(11):1105–1112

Article  PubMed  PubMed Central  Google Scholar 

Sanders DB et al (2016) International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 87(4):419–425

Article  PubMed  PubMed Central  Google Scholar 

Sharshar T, Porcher R, Demeret S, Tranchant C, Gueguen A, Eymard B, Nadaj-Pakleza A, Spinazzi M, Grimaldi L, Birnbaum S, Friedman D, Clair B, MYACOR Study Group (2021) Comparison of corticosteroid tapering regimens in myasthenia gravis: a randomized clinical trial. JAMA Neurol 78(1):426–433. https://doi.org/10.1001/jamaneurol.2020.5407

Article  PubMed  PubMed Central  Google Scholar 

Shi F, Xue R, Zhou X et al (2021) Telitacicept as a BLyS/ APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol 43(6):666–673

Article  PubMed  CAS  Google Scholar 

Skeie GO, Apostolski S, Evoli A et al (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17:893–902

Article  PubMed  CAS  Google Scholar 

Vissing J, Jacob S, Fujita KP et al (2020) “Minimal symptom expression” in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol 267:1991–2001

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang S, Breskovska I, Gandhy S et al (2018) Advances in autoimmune myasthenia gravis management. Expert Rev Neurother 18:573–588

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yao X, Ren Y, Zhao Q et al (2021) Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. Eur J Pharm Sci 159:105704

Article  PubMed  CAS  Google Scholar 

Yin J, Zhao M, Xu X, Zhang M, Xu Z, Li Z, Qin X, Li Z, Zhao C, Zhou H, Ma Y, Cao W, Wang G, Lin Y, Zhang J, Zhang X, Cai H, Qian W, Wang Y, Zhang X, Liu G, Wang J, Qiu W, Min L, Li J, Deng H, Chu L, Zhang Y, Fang J (2024) A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis. Eur J Neurol 31(8):e16322

Article